Is bosutinib/bosutinib an antihypertensive drug? What is it also called?

Bosutinib/Bosutinib is not an antihypertensive drug, but an anticancer drug for chronic myelogenous leukemia (CML). It is an oral tyrosine kinase inhibitor mainly used to treat patients with BCR-ABL-positive chronic myelogenous leukemia. Bosutinib prevents the growth and survival of cancer cells by selectively inhibiting the tyrosine kinase produced by the BCR-ABL fusion gene.

The chemical structure of bosutinib is different from other tyrosine kinase inhibitors such as imatinib, dasatinib and nilotinib, so its mechanism of action and drug resistance characteristics are also different. Its trade name is "Bosulif" and it is widely used clinically around the world. Bosutinib is approved for the treatment of patients who are resistant or intolerant to first-generation TKIs, especially after showing good efficacy in clinical trials.

Regarding the relationship between bosutinib and antihypertensive drugs, although some patients may experience mild hypertension or other cardiovascular-related adverse reactions when using bosutinib, this does not mean that bosutinib itself has antihypertensive effects. These side effects are usually related to physiological changes in the body caused by the drug rather than a direct effect of the drug. Therefore, monitoring of blood pressure is necessary in patients receiving bosutinib, and physicians may need to adjust and manage the blood pressure based on the patient's specific circumstances.

In addition, the indications of bosutinib are mainly concentrated in the field of leukemia, and its mechanism of action is completely different from antihypertensive drugs (such asACE inhibitors, calcium channel blockers, diuretics, etc.). Antihypertensive drugs typically lower blood pressure by relaxing blood vessels or reducing workload on the heart, while bosutinib exerts its anticancer effects by inhibiting tumor cell proliferation.

Reference materials:https://go.drugbank.com/drugs/DB06616